Chapter 39 — Quiz

DataField.Dev

Chapter 39 — Quiz

Twenty-two items. Answer key at the end. Items are drawn from Chapter 39, with several requiring Chapters 5, 19, and 38.

1. According to §39.1, the peptide conversation goes badly primarily because:

a) most clinicians are poorly trained in pharmacology
b) most patients are unwilling to accept expert judgment
c) both parties arrive braced against an expected behavior, and each optimizes against it
d) the compounds involved are genuinely too obscure to discuss

2. §39.2 gives four clinical reasons to disclose everything you are taking. Which of the following is not one of them?

a) differential diagnosis
b) interaction checking
c) demonstrating good faith to your clinician
d) peri-operative safety

3. Why do GLP-1 receptor agonists create a peri-operative consideration?

a) they thin the blood, raising bleeding risk during surgery
b) they slow gastric emptying, so a correctly fasted patient may still have retained gastric contents, raising aspiration risk under sedation
c) they interact with all common anesthetic agents
d) they suppress the immune response, delaying wound healing

4. The chapter says the reasons for disclosure should be given clinically rather than morally. The argument is that:

a) clinicians respond better to clinical language
b) the moral framing turns disclosure into a confession, and people minimize when they confess
c) moral reasoning has no place in medicine
d) the clinical reasons are more numerous

5. A patient reports "no change at all" from something they have been taking. According to §39.3, this is:

a) not worth mentioning, since nothing happened
b) genuinely useful information that is almost never reported
c) evidence that the compound does not work
d) a sign the patient was not taking it correctly

6. The asymmetry described in §39.3 is that:

a) the clinician has more information than the patient in every respect
b) the patient usually knows the marketing claim and not the compound; the clinician usually knows the drug class and not the marketing
c) the patient has more time than the clinician
d) the clinician is legally exposed and the patient is not

7. "What's the evidence for this in someone like me?" is testing:

a) the endpoint
b) the comparator
c) the population
d) the stopping rule

8. STEP 1 and STEP 2 differed by design in which respect?

a) the dose studied
b) the duration of follow-up
c) whether enrolled participants had type 2 diabetes
d) whether the comparator arm received lifestyle intervention

9. "What would you expect to see, and by when?" is valuable primarily because it:

a) commits the clinician to a guarantee
b) converts a vague hope into a falsifiable prediction
c) establishes the dose
d) shortens the appointment

10. The chapter says the stopping rule must be asked before starting because:

a) clinicians will not answer it later
b) it is nearly impossible to ask honestly once you are invested
c) it is required for informed consent
d) the answer changes once the compound is in the body

11. §39.5 recommends bringing to an appointment:

a) a folder of everything you have read
b) one study, in the form of the actual paper or abstract
c) a printed summary of online discussion
d) nothing — clinicians resent patient research

12. The four basics you should know about a study before discussing it are:

a) journal, author, year, funding
b) population, endpoint, comparator, size
c) dose, duration, route, frequency
d) mechanism, safety, cost, availability

13. Which pairing correctly matches §39.6's three sentences to their meanings?

a) "we don't know" = the evidence is absent; "it doesn't work" = the evidence exists and is negative; "I don't know" = this clinician has not looked into it
b) "we don't know" = this clinician has not looked into it; "it doesn't work" = the evidence is absent; "I don't know" = the evidence exists and is negative
c) all three mean approximately the same thing in practice
d) "we don't know" = the evidence exists and is negative; "it doesn't work" = this clinician has not looked into it; "I don't know" = the evidence is absent

14. Which of §39.6's three sentences is the strongest claim about the state of the world?

a) "we don't know"
b) "it doesn't work"
c) "I don't know"
d) they are equally strong

15. §39.7's diagnostic for whether a dismissal is a failure of the conversation is whether the clinician:

a) raised their voice
b) engaged with the claim or dismissed the category
c) offered an alternative
d) documented the discussion

16. A category dismissal is described as a failure of the conversation even when the verdict is correct, because it:

a) exposes the clinician legally
b) teaches the patient not to disclose next time
c) wastes appointment time
d) is unprofessional in itself

17. The repair move the chapter recommends after a category dismissal is:

a) asking for a referral
b) presenting the study you brought
c) asking "what would change your mind?"
d) changing clinicians

18. According to §39.8, a clinician's enthusiastic recommendation of a compound is:

a) stronger evidence than a refusal, because it takes more professional courage
b) weaker evidence than a refusal
c) not evidence about a molecule at all — it is a clinical judgment, like a refusal
d) evidence only if the clinician is a specialist

19. The chapter's conclusion about a practice that dispenses what it recommends is that a conflict of interest is:

a) evidence of dishonesty
b) a reason to check the evidence, not evidence of dishonesty
c) irrelevant if the clinician is licensed
d) grounds for reporting the practice

20. Which of the following can medical supervision not provide for use of an unapproved compound?

a) baseline and interval monitoring
b) interaction checking against your full medication list
c) a defined response pathway if something goes wrong
d) evidence about whether the compound works

21. §39.9 warns readers not to misread which of the following as a personality trait?

a) a clinician's institutional or licensing constraints
b) a clinician's running late
c) a clinician's specialty training
d) a clinician's documentation habits

22. According to §39.10, a patient who reports back what actually happened — including when nothing happened — is:

a) wasting appointment time on a closed matter
b) contributing the only kind of systematic information ever generated about compounds the gray market cannot study
c) generating evidence equivalent to a small trial
d) obliged to do so under most clinical guidelines

Answer key

**1 — c.** §39.1. Neither party is behaving badly; the room is shaped so that each optimizes against the other's expected behavior. Options (a) and (b) both locate the failure in one person's deficiency, which is the reading the chapter explicitly rejects. **2 — c.** The four are differential diagnosis, interactions, surgery and emergencies, and monitoring. Demonstrating good faith is a *moral* reason, and §39.2's central argument is that the moral framing is what makes people conceal. **3 — b.** Slowed gastric emptying is part of how the class produces satiety. Retained gastric contents raise aspiration risk when protective airway reflexes are suppressed. Guidance has evolved from a blanket hold recommendation toward individualized assessment; the point for the patient is not to know the current rule but to make sure the anesthetist knows about the exposure. **4 — b.** A person who experiences disclosure as a confession will minimize, and minimizing produces exactly the failures the section describes. **5 — b.** People volunteer changes and stay silent about their absence, which is one of the mechanisms §39.10 identifies as biasing clinician impressions toward success. Note that (c) is too strong — one person's non-response is not evidence that a compound does not work. **6 — b.** Each party holds half the picture. The conversation works when both halves reach the table. **7 — c.** The population question, from Chapter 5. The three load-bearing words are *like me*. **8 — c.** STEP 1 enrolled adults with overweight or obesity without diabetes; STEP 2 enrolled adults with type 2 diabetes. Average weight loss was smaller in the population with diabetes. Same drug, different population, different result. **9 — b.** A prediction with a magnitude and a date can fail, which is the whole value. Without one there is no point at which the honest conclusion is available, which is the escalating-dose trap of Chapter 2 §2.8. Note (a) is wrong — an expectation is not a guarantee. **10 — b.** Chapter 6's testimonial dynamic describes how reinterpretation happens once a person is invested. The rule has to be set by the version of you that is still neutral. **11 — b.** One study, the paper or abstract rather than an article about it. The folder does not work, and (d) is wrong — the chapter wants you to read. **12 — b.** Population, endpoint, comparator, size. If you cannot state all four from memory, you have not read the study closely enough to discuss it. **13 — a.** This distinction is the highest-yield content in the section, and asking which one you are hearing costs nothing. **14 — b.** "It doesn't work" asserts that evidence exists and is negative — a strictly stronger claim than "the evidence is absent." Chapter 28's nesiritide is the canonical case of a compound that looked excellent until an adequately powered trial said otherwise. **15 — b.** "There's no good human evidence, and here's what there is" engages. "That's all nonsense, where did you read that" dismisses the category. **16 — b.** It degrades the channel that all future information has to travel through — the outcome §39.2 spent its length trying to prevent. **17 — c.** The same question Field 12 of the dossier asks. It is not a challenge, and the answer is informative in all three of its usual forms. **18 — c.** Both a recommendation and a refusal are clinical judgments. Neither is evidence about a molecule. Chapter 38 §38.10 established the parallel: a prescription is a clinical judgment, not a demonstration. **19 — b.** Chapter 42's conclusion, and the chapter is explicit that dispensing practices are not thereby corrupt — many dispense for sound reasons. The structure raises the value of checking; it settles nothing. **20 — d.** Supervision adds monitoring, interaction checking, and a response pathway (Chapter 19 §19.7). It adds no evidence and cannot detect harms nobody knows to monitor for. It changes the risk profile without changing the unknowns. **21 — a.** Formularies, insurer conditions, licensing-board positions, and institutional protocols all produce "I can't do that," which sounds identical to "I don't want to." Asking whether it is a policy matter or a clinical judgment distinguishes them without damaging the relationship. **22 — b.** The gray market has no trials, no registries, no adverse-event reporting, and no follow-up. Observations reaching clinicians one patient at a time are the only systematic information generated. Note that (c) overclaims — this is weak, uncontrolled evidence, and the chapter says so.